The news is PrecivityAD2, a blood test that aids Alzheimer's evaluation, was cleared for symptomatic adults age 40 and older on Aug. 20, 2026.
For younger-onset Alzheimer's, meaning diagnosis before age 65, caregivers now have a cleared blood aid that can prompt earlier referral and planning. Early symptoms in midlife are often mistaken for stress, depression, or menopause. A timely medical workup can separate those causes and start support sooner.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What changed for families in their 40s and 50s?
- How does the test work?
- How strong is the result?
- What does the clearance not allow?
- What practical step should you take next?
What changed for families in their 40s and 50s?
According to C2N Diagnostics in its August announcement, FDA cleared PrecivityAD2 on Aug. 20, 2026 for adults age 40 and older with cognitive signs. It is the first cleared blood test with a lower age bound of 40.
Young-onset Alzheimer's means diagnosis before age 65 and accounts for about 5-10% of cases, according to the Social Security Administration. For caregivers, the shift is simple. A symptomatic adult from age 40 can now discuss an FDA-cleared blood aid that may speed referral, treatment talks, and care planning.
How does the test work?
According to NeurologyLive in its test description, PrecivityAD2 uses high-resolution mass spectrometry to measure plasma Aβ42/40 and percent p-tau217/np-tau217. It combines both results into an Amyloid Probability Score 2 that estimates brain amyloid likelihood.
Amyloid buildup in the brain is a hallmark change linked to Alzheimer's. The score does not by itself diagnose dementia; the clinician reads it with history, exam, and cognitive testing.
How strong is the result?
According to NeurologyLive in its coverage of the validation data, positive results showed 97.6% positive predictive value in 1,142 symptomatic adults. Negative results showed 93.1% negative predictive value versus amyloid PET or spinal-fluid biomarkers.
About 17.3% of results fell in an intermediate likely-positive band with only 77.3% positive predictive value, according to NeurologyLive. Those results need clinical judgment and sometimes confirmatory PET or spinal-fluid testing.
What does the clearance not allow?
Under its FDA clearance described in the FDA clearance letter, the test is an aid used with history, exam, and cognitive testing. It is not cleared for screening people without symptoms or as a standalone Alzheimer's diagnosis. The Alzheimer's Association issued a July 2025 specialty-care guideline on blood biomarker use.
It permits qualifying tests for triage, and tests with higher accuracy as a substitute for PET or spinal-fluid tests. The thresholds are at least 90% sensitivity with at least 75% specificity for triage, and at least 90% for both as a substitute. Families should ask whether the clinic uses the result for triage or as a replacement, and why.
What practical step should you take next?
Start with the primary-care clinician or dementia specialist if memory, language, judgment, or daily function has changed. Bring specific dates and examples, not general worry. Ask these questions at the visit.
Write down the answers and who will follow up. Bring a one-page timeline of symptom onset, work impact, medications, and family history to that visit. Ask who will explain the score and arrange follow-up.
- Is a blood biomarker aid appropriate with these symptoms at this age?
- What will a positive, negative, or intermediate score change?
- Will we need PET or spinal-fluid confirmation, and where is referral?
You Might Also Like
- The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: What Family Caregivers Should Know About the News
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: What Family Caregivers Should Know About the News
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: What Family Caregivers Should Know About the News
